Learn about clinical breakthroughs and advances in patient care during the educational symposia at the Society of Critical Care Medicine’s (SCCM) 45th Critical Care Congress. Each stimulating session is presented by leading experts in critical care and offers a thorough analysis of the developments and issues affecting most intensive care unit (ICU) environments. These sessions are complimentary for all Congress registrants, and no additional registration is needed to attend.
Bleeding Management and Reversal Strategies for the DOAC Patient: New and Future Approaches
Supported by an educational grant from Portola Pharmaceuticals
This session will examine general approaches and prothrombin complex concentrates. Reversal strategies for dabigatran and Xa inhibitors will also be reviewed.
Every Patient Has a Story: Individualizing the Management of Invasive Fungal Infections in the Critical Care Setting
Supported by an educational grant from Astellas Pharma Global Development, Inc.
This session will explore invasive fungal infections in the critical care setting and how to identify and overcome diagnostic challenges. Managing at-risk patients and optimizing antifungal therapy will also be discussed.
Improving Clinical Outcomes and Pathogen-Directed Therapy for Serious Bacterial Infections in the Critical Care Setting
Supported by an educational grant from Merck & Co., Inc.
This session will offer an overview of epidemiology and current guidelines for multidrug-resistant bacterial infections, as well as strategies for implementing a pathogen-directed approach to tailoring therapies and new and emerging therapeutic options for treatment.
Optimizing Treatment and Improving Care Transitions in Chronic Heart Failure
Supported by an educational grant from Amgen
This session will review the epidemiology, pathophysiology and diagnosis of chronic heart failure and how strategies to decrease hospital readmission rates and overall costs through better diagnosis and disease management impact patient outcomes. Safety, efficacy, and clinical application of the current and emerging therapeutics, the new recommendation for the management of chronic heart failure, and appropriate strategies to optimize pharmacological treatment of chronic heart failure will be discussed.
The Role of Biomarkers in Acute Kidney Injury (AKI) Risk-Assessment
Supported by an educational grant from Astute Medical, Inc.
This session will discuss the pathophysiology, etiology and epidemiology of AKI. Risk stratification scores, first-generation AKI markers and new markers of AKI and risk assessment will be examined.
Tailoring Therapy and Improving Outcomes in Patients with Acute Decompensated Heart Failure (ADHF)
Supported by an educational grant from Novartis Pharmaceuticals Corporation
This session will review the diagnosis and classification of ADHF, existing therapies, new guidelines and the safety and efficacy data for new and emerging treatment therapies, as well as identify strategies for individualizing therapy to improve patient outcomes.
These symposia will be held Monday, February 22, 2016, at the Orange County Convention Center. Seating is on a first-come, first-served basis. A continental breakfast will be available before each symposium, beginning at 6:00 a.m. The sessions will start promptly at 6:30 a.m.